Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics

Acumen Pharmaceuticals, Inc. (ABOS): $2.65

0.04 (-1.49%)

POWR Rating

Component Grades








Add ABOS to Watchlist
Sign Up

Industry: Biotech




#294 of 345

in industry

ABOS Price/Volume Stats

Current price $2.65 52-week high $11.31
Prev. close $2.69 52-week low $1.81
Day low $2.62 Volume 182,314
Day high $2.70 Avg. volume 492,286
50-day MA $3.00 Dividend yield N/A
200-day MA $4.77 Market Cap 153.46M

ABOS Stock Price Chart Interactive Chart >

Acumen Pharmaceuticals, Inc. (ABOS) Company Bio

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.

ABOS Latest News Stream

Event/Time News Detail
Loading, please wait...

ABOS Latest Social Stream

Loading social stream, please wait...

View Full ABOS Social Stream

Latest ABOS News From Around the Web

Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript November 13, 2023 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.31. Presentation: Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast. At this time, all participants are in […]

Yahoo | November 14, 2023

Q3 2023 Acumen Pharmaceuticals Inc Earnings Call

Q3 2023 Acumen Pharmaceuticals Inc Earnings Call

Yahoo | November 14, 2023

Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update

Key Developments Include Progress on Alzheimer's Treatment and New Funding Agreements

Yahoo | November 13, 2023

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?

InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, and ABOS.

Yahoo | November 13, 2023

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has e

Yahoo | November 13, 2023

Read More 'ABOS' Stories Here

ABOS Price Returns

1-mo 21.00%
3-mo -55.31%
6-mo -45.59%
1-year -52.68%
3-year N/A
5-year N/A
YTD -50.93%
2022 -20.12%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!